PubMed چکیده/رکورد

Integration of Artificial Intelligence in the Pharmaceutical Sector: From Drug Discovery, Clinical Care, Manufacturing, to Market Delivery-A Review.

استودیوی صوتی مقاله

پخش حرفه‌ای فارسی و انگلیسی

در حال بررسی نسخه‌های صوتی ذخیره‌شده…

صوت تولیدشده با هوش مصنوعی است. برای کاربرد علمی یا درمانی، متن و منبع اصلی را بررسی کنید.
خواندن هوشمند فارسی و انگلیسی در حال آماده‌سازی صداهای مرورگر…
تنظیم صدای طبیعی و سرعت

صداهایی که در نامشان «Natural»، «Neural» یا «Online» دیده می‌شود معمولاً طبیعی‌ترند. انتخاب صدا به صداهای نصب‌شده در ویندوز و مرورگر شما بستگی دارد.

چکیده اصلی

Artificial Intelligence (AI) is revolutionizing the pharmaceutical industry by enhancing efficiency, precision, and personalization in drug discovery, development, and patient care. This review explores the diverse applications of AI in pharmacy, including drug discovery, formulation development, target identification, hit discovery, and lead optimization. The review explains the clinical trial design and predictive modeling in the crucial implementation of AI. Clinical care for diagnosis, medical image analysis, and early disease detection with sharp clinical decisions are the new directives of AI, as explained. Personalized medicine and pharmacovigilance also include AI to improve outcomes. Community and hospital pharmacies use AI to check treatment plans and drug interactions, as highlighted. Pharma manufacturing uses AI for process optimization, quality management, and supply chain management, resulting in better output. Pharma marketing also uses AI to predict trends and analyze the market. Sales forecasting and compliance monitoring are additional areas in which AI is increasingly being applied. Academic research has also benefited from AI applications. However, regulatory compliance and cultural barriers remain important challenges to AI adoption. Future research directions and emerging opportunities have the potential to further advance the pharmaceutical sector. The challenges associated with AI across these domains are discussed to provide a balanced perspective. This review provides an integrated overview of AI applications across the pharmaceutical sector and the associated challenges.

متن کامل اصلی

متن در JumpToDate ذخیره نشده است.

برای بررسی دسترسی کتابخانه‌ای یا خرید، رکورد اصلی را باز کنید.

رفتن به منبع اصلی

کلیدواژه‌ها

Artificial intelligenceclinical pharmacydrug discovery.pharmacovigilancepharmacy
در همین زیرشاخه

مقاله‌های مرتبط

PubMed2026

Real-world pharmacoclinical implementation of risdiplam under a national SMA protocol: A hospital pharmacy registry-based case series.

BACKGROUND: Spinal muscular atrophy (SMA) is a rare neuromuscular disorder treated with disease-modifying therapies such as risdiplam. In Spain, its use is regulated by a national pharmacoclinical protocol that requires structured monitoring. OBJECTIVES: To evaluate real-world use, protocol adherence and registry completeness of risdiplam in routine clinical practice. METHODS: A retrospective registry-based case series was conducted in…

PubMed2026

Sex Differences in Prescribing Patterns of Anticholinergics and β3-Adrenoceptor Agonists for Overactive Bladder: A Nationwide Study in Japan, FY2017-FY2024.

OBJECTIVES: Drug treatment for overactive bladder (OAB) is changing, with an increasing share of β3-adrenoceptor agonists relative to anticholinergics, but it is not known how far this change has progressed in older people, who are most vulnerable to the risks of anticholinergics. We examined the use of these drugs in Japan by age and sex, and analyzed changes in anticholinergic burden using a large database. METHODS: We analyzed outpa…

PubMed2026

ARMED: an Australian cohort retrospective observational study to understand motivations for switching and clinical outcomes of individuals switching to dolutegravir/lamivudine.

BACKGROUND: Although clinical trials and real-world studies demonstrate the efficacy and tolerability of dolutegravir and lamivudine (DTG + 3TC), Australian real-world evidence remains limited despite differences in access to health care and prescribing context. Here, we present the motivations for switching to DTG/3TC (a fixed-dose, single-tablet regimen) and treatment outcomes. METHODS: We performed a retrospective, observational ana…

PubMed2026

Antibiotic prescribing that aligns with a host-protein test at US acute care settings is associated with fewer subsequent hospitalisations.

BACKGROUND: Differentiating bacterial from viral infections in acute care is challenging, often leading to inappropriate antibiotic use. MeMed BV (MMBV) is a host-protein test integrating TNF-related apoptosis-inducing ligand, induced protein-10 and C-reactive protein to distinguish infection aetiology. We evaluated whether alignment between MMBV results and antibiotic prescribing is associated with downstream clinical outcomes and cos…